Comparing Hepatic GSD Proteomic Responses
In hepatocyte-specific edited male mice, GSD Ia and GSD Ib produced largely comparable liver transcriptomic and proteomic responses, while the measured metabolic and regulatory disturbances were generally greater in the GSD Ia model.
> Research explainer: This briefing examines verified primary research published 82 days before the briefing date. It is not a same-day research update and does not provide medical advice.
Evidence
This research explainer examines a study of hepatic glycogen storage disease (GSD) type Ia and Ib in mice. The investigators used hepatocyte-specific, somatic CRISPR/Cas9 editing to target G6pc for GSD Ia and Slc37a4 for GSD Ib, then compared biochemical, histological, transcriptomic, and proteomic findings with controls. The supplied evidence describes male mice and a liver-focused model, so its direct observations concern experimental hepatic disease biology rather than people.
Both edited groups showed hepatomegaly, fasting hypoglycemia, hyperlactatemia, and increased plasma uric acid relative to controls. These measured changes were somewhat more pronounced in the GSD Ia group. Both subtypes also had similar reductions in hepatic acetyl-CoA precursor-pool enrichment and increased de novo biosynthesis of hepatic stearate and oleate. The shared direction of these measurements fits the study’s overall finding of comparable biochemical and regulatory responses across the two liver models.
The comparison also identified differences. Mildly elevated plasma triglycerides and hepatic phosphate sugars were reported only in the GSD Ia mice. At the molecular level, transcriptomic and proteomic responses were largely similar between GSD Ia and GSD Ib livers. However, altered mRNAs and protein levels related to NOD signaling, infection and inflammation, liver disease, and chemical carcinogenesis were somewhat more pronounced in the GSD Ia model. The supplied material reports these as pathway- and category-level observations; it does not name or quantify individual altered proteins.
Analysis — Proteomic convergence with greater Ia disturbance
The proteomics result is most useful as a comparative signal. Editing either of two genes that support the final handling of glucose-6-phosphate in hepatocytes yielded largely similar liver transcriptomic and proteomic responses. In this model, that convergence provides molecular context for the overlapping biochemical phenotype: both groups developed the listed abnormalities and showed similar changes in acetyl-CoA precursor-pool enrichment and newly synthesized stearate and oleate. It supports interpreting the two edits as producing related hepatic regulatory disruption within the measurements reported.
The distinctions matter because they are selective rather than wholesale. GSD Ia alone showed mildly elevated plasma triglycerides and hepatic phosphate sugars, while several biochemical changes were somewhat more pronounced in GSD Ia. Protein- and mRNA-level changes assigned to NOD signaling, infection and inflammation, liver disease, and chemical carcinogenesis were also somewhat more pronounced in GSD Ia. Together, these observations support the study’s model-bounded conclusion that metabolic disturbance was more severe in hepatocyte-specific GSD Ia than in hepatocyte-specific GSD Ib.
Proteomics here should not be read as a list of confirmed disease biomarkers or as evidence that a particular protein drives a human complication. The supplied abstract provides no protein identities, effect sizes, statistical thresholds, tissue-cell resolution, or validation experiments for individual proteins. Accordingly, the strongest supported interpretation is directional and comparative: the study detected broadly shared liver molecular responses, alongside a greater degree of disturbance in the GSD Ia mouse model for the reported outcomes.
Limitations
This evidence comes from hepatocyte-specific CRISPR/Cas9-edited male mice, not human patients. It therefore does not establish human disease mechanisms, clinical efficacy, treatment effects, or conclusions for any individual. The editing approach was somatic and liver focused, whereas the source notes that the relevant genes have differing expression patterns beyond hepatocytes. The reported comparison is also bounded to the study’s controls, timing, measured outcomes, and experimental model.
The source material supplied for this briefing gives pathway-level and protein-level summaries but not the identities or individual quantitative changes of proteins. That limits protein-specific interpretation and prevents assessment of whether a particular molecular change is replicated across methods or models. Finally, “somewhat more pronounced” is the source’s qualitative comparative framing; without underlying numerical results in the supplied evidence, it should not be converted into a precise magnitude or ranking beyond the outcomes described.